A Phase 3 Study of NTLA-2001 in ATTRv-PN

NCT06672237 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuromuscular Disease
Neuromuscular Diseases (NMD)
Neurodegenerative Disease
Neurodegenerative Disease, Hereditary
Neurodegenerative Diseases
Neuromuscular Diseases
Nerve Disorders
Nervous System Disease
Nervous System Diseases
Genetic Disease, Inborn
Amyloidosis, Familial
Amyloidosis, Hereditary
Amyloidosis
Polyneuropathies
Amyloid Neuropathies
Amyloid Neuropathies, Familial
Peripheral Nervous System Disease
Peripheral Nervous System Diseases
Metabolism, Inborn Errors
Metabolic Diseases

Interventions

BIOLOGICAL: nexiguran ziclumeran
DRUG: Normal Saline as Placebo

Sponsor

Intellia Therapeutics

Collaborators

[object Object]